Responses to parliamentary questions
Question from Deputy Ken O’Flynn - PQ 38847-26
Deputy O'Flynn asked about the reimbursement consideration for omaveloxolone (skyclarys). Read the HSE response.
From: Communications and public affairs
Published: May 2026
Updated: July 2026
Documents
Summary
To ask the Minister for Health if any budget impact assessment, cost projection, prevalence estimate, or epidemiological model was prepared in advance of reimbursement consideration for omaveloxolone (skyclarys); and the details of same.
This is a beta version - your feedback will help us to improve it